Type 2 Diabetes is more than 2-fold higher in individuals with NAFLD and often evolves with normal liver enzymes.

LIVERFAStTM accurately identifies severe fibrosis and cirrhosis in both patients with or without type 2 diabetes irrespective of liver enzyme levels.

NASH related cirrhosis is disproportionately high in those with type 2 diabetes and is now on a trajectory to become the most common indication for liver transplantation in the U.S.

LIVERFAStTM accurately identifies cirrhosis in subjects with all biochemistry inside the normal laboratory range.